# PeptideScanner evidence objects: Albiglutide

Every published version of the records placed with Albiglutide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/albiglutide.json. Selected public evidence only; not medical advice.

- Objects: 19
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00838903-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT00838903

> PeptideScanner retained ClinicalTrials.gov record NCT00838903 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct00838903-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00838903-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct00838903-albiglutide-v1
- Content SHA-256: `16968e3346883c93c3060c153a248edcc2e6fcfc5ac1c2465e07ff1b25adf907`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00838903 ([`ctg-observation-nct00838903-2017-01-09-ebd7ff01e2e9`](#source-ctg-observation-nct00838903-2017-01-09-ebd7ff01e2e9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00838903 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct00838903-2017-01-09-ebd7ff01e2e9`](#source-ctg-observation-nct00838903-2017-01-09-ebd7ff01e2e9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00838903 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct00838903-2017-01-09-ebd7ff01e2e9`](#source-ctg-observation-nct00838903-2017-01-09-ebd7ff01e2e9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00838903-2017-01-09-ebd7ff01e2e9`](#source-ctg-observation-nct00838903-2017-01-09-ebd7ff01e2e9))

### Sources

<a id="source-ctg-observation-nct00838903-2017-01-09-ebd7ff01e2e9"></a>
- **ClinicalTrials.gov record NCT00838903 · retained source version 2017-01-09:ebd7ff01e2e9611ec3fbbb8e0ca74c4612f5a5cad458fdf5ffa617fac51eedb9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00838903) (`ctg-observation-nct00838903-2017-01-09-ebd7ff01e2e9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00838903." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct00838903-albiglutide-v1 SHA-256: 16968e3346883c93c3060c153a248edcc2e6fcfc5ac1c2465e07ff1b25adf907.

---

<a id="clinicaltrials-gov-nct00838916-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT00838916

> PeptideScanner retained ClinicalTrials.gov record NCT00838916 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct00838916-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00838916-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct00838916-albiglutide-v1
- Content SHA-256: `1bd539b4e5f6229b83979fa32aedfc5a186d5a88ab8d388e8e420e6929379e70`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00838916 ([`ctg-observation-nct00838916-2017-01-09-24a622b52f62`](#source-ctg-observation-nct00838916-2017-01-09-24a622b52f62))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00838916 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct00838916-2017-01-09-24a622b52f62`](#source-ctg-observation-nct00838916-2017-01-09-24a622b52f62))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00838916 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct00838916-2017-01-09-24a622b52f62`](#source-ctg-observation-nct00838916-2017-01-09-24a622b52f62))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00838916-2017-01-09-24a622b52f62`](#source-ctg-observation-nct00838916-2017-01-09-24a622b52f62))

### Sources

<a id="source-ctg-observation-nct00838916-2017-01-09-24a622b52f62"></a>
- **ClinicalTrials.gov record NCT00838916 · retained source version 2017-01-09:24a622b52f62429db1c1939fb1581c5805febc2b36d8124ed336450ad687d5a5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00838916) (`ctg-observation-nct00838916-2017-01-09-24a622b52f62`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00838916." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct00838916-albiglutide-v1 SHA-256: 1bd539b4e5f6229b83979fa32aedfc5a186d5a88ab8d388e8e420e6929379e70.

---

<a id="clinicaltrials-gov-nct00839527-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT00839527

> PeptideScanner retained ClinicalTrials.gov record NCT00839527 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct00839527-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00839527-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct00839527-albiglutide-v1
- Content SHA-256: `d866331a97628c25bd8792267ad7c9c82d7f44cb0a41f840264e2e84584fb2b6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00839527 ([`ctg-observation-nct00839527-2017-01-09-e114864963d6`](#source-ctg-observation-nct00839527-2017-01-09-e114864963d6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00839527 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct00839527-2017-01-09-e114864963d6`](#source-ctg-observation-nct00839527-2017-01-09-e114864963d6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00839527 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct00839527-2017-01-09-e114864963d6`](#source-ctg-observation-nct00839527-2017-01-09-e114864963d6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00839527-2017-01-09-e114864963d6`](#source-ctg-observation-nct00839527-2017-01-09-e114864963d6))

### Sources

<a id="source-ctg-observation-nct00839527-2017-01-09-e114864963d6"></a>
- **ClinicalTrials.gov record NCT00839527 · retained source version 2017-01-09:e114864963d67ea61351e4422eca6b5e72fc1ee47ae8468b3a2630eae542c9eb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00839527) (`ctg-observation-nct00839527-2017-01-09-e114864963d6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00839527." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct00839527-albiglutide-v1 SHA-256: d866331a97628c25bd8792267ad7c9c82d7f44cb0a41f840264e2e84584fb2b6.

---

<a id="clinicaltrials-gov-nct00849017-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT00849017

> PeptideScanner retained ClinicalTrials.gov record NCT00849017 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct00849017-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00849017-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct00849017-albiglutide-v1
- Content SHA-256: `d3b7df46541efe812064739bc847c24f2679bdfee015856ebaaac172f1263852`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00849017 ([`ctg-observation-nct00849017-2017-01-09-ebc591ba54ee`](#source-ctg-observation-nct00849017-2017-01-09-ebc591ba54ee))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00849017 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct00849017-2017-01-09-ebc591ba54ee`](#source-ctg-observation-nct00849017-2017-01-09-ebc591ba54ee))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00849017 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct00849017-2017-01-09-ebc591ba54ee`](#source-ctg-observation-nct00849017-2017-01-09-ebc591ba54ee))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00849017-2017-01-09-ebc591ba54ee`](#source-ctg-observation-nct00849017-2017-01-09-ebc591ba54ee))

### Sources

<a id="source-ctg-observation-nct00849017-2017-01-09-ebc591ba54ee"></a>
- **ClinicalTrials.gov record NCT00849017 · retained source version 2017-01-09:ebc591ba54ee9267bcaf36e6345deca9b69dc6c4605f02040869f0303bf0c01d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00849017) (`ctg-observation-nct00849017-2017-01-09-ebc591ba54ee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00849017." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct00849017-albiglutide-v1 SHA-256: d3b7df46541efe812064739bc847c24f2679bdfee015856ebaaac172f1263852.

---

<a id="clinicaltrials-gov-nct00849056-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT00849056

> PeptideScanner retained ClinicalTrials.gov record NCT00849056 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct00849056-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00849056-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct00849056-albiglutide-v1
- Content SHA-256: `2bbeedecb5d730f941ddaaed7824d828a5f5d469ee8566af4381ceaeb0d9eedb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00849056 ([`ctg-observation-nct00849056-2017-01-09-eb2bf44dcc00`](#source-ctg-observation-nct00849056-2017-01-09-eb2bf44dcc00))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00849056 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct00849056-2017-01-09-eb2bf44dcc00`](#source-ctg-observation-nct00849056-2017-01-09-eb2bf44dcc00))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00849056 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct00849056-2017-01-09-eb2bf44dcc00`](#source-ctg-observation-nct00849056-2017-01-09-eb2bf44dcc00))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00849056-2017-01-09-eb2bf44dcc00`](#source-ctg-observation-nct00849056-2017-01-09-eb2bf44dcc00))

### Sources

<a id="source-ctg-observation-nct00849056-2017-01-09-eb2bf44dcc00"></a>
- **ClinicalTrials.gov record NCT00849056 · retained source version 2017-01-09:eb2bf44dcc0016430afc8da70effa72c06328311e97ec106fd49d185cb194f16** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00849056) (`ctg-observation-nct00849056-2017-01-09-eb2bf44dcc00`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00849056." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct00849056-albiglutide-v1 SHA-256: 2bbeedecb5d730f941ddaaed7824d828a5f5d469ee8566af4381ceaeb0d9eedb.

---

<a id="clinicaltrials-gov-nct00938158-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT00938158

> PeptideScanner retained ClinicalTrials.gov record NCT00938158 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-07-21, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct00938158-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-07-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00938158-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct00938158-albiglutide-v1
- Content SHA-256: `3395f18a4a835eefbd0a0ac02f826a628dc9bcd7b868cf2c026a3097062a1e22`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00938158 ([`ctg-observation-nct00938158-2017-07-21-2a341bf8c629`](#source-ctg-observation-nct00938158-2017-07-21-2a341bf8c629))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00938158 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-07-21, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct00938158-2017-07-21-2a341bf8c629`](#source-ctg-observation-nct00938158-2017-07-21-2a341bf8c629))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00938158 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-07-21, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct00938158-2017-07-21-2a341bf8c629`](#source-ctg-observation-nct00938158-2017-07-21-2a341bf8c629))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00938158-2017-07-21-2a341bf8c629`](#source-ctg-observation-nct00938158-2017-07-21-2a341bf8c629))

### Sources

<a id="source-ctg-observation-nct00938158-2017-07-21-2a341bf8c629"></a>
- **ClinicalTrials.gov record NCT00938158 · retained source version 2017-07-21:2a341bf8c629cfecb3642f8fa10ddb1ec5f09a326345030489ddb0b2c9b50b81** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00938158) (`ctg-observation-nct00938158-2017-07-21-2a341bf8c629`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00938158." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct00938158-albiglutide-v1 SHA-256: 3395f18a4a835eefbd0a0ac02f826a628dc9bcd7b868cf2c026a3097062a1e22.

---

<a id="clinicaltrials-gov-nct01077505-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT01077505

> PeptideScanner retained ClinicalTrials.gov record NCT01077505 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct01077505-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-06-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01077505-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct01077505-albiglutide-v1
- Content SHA-256: `5ec932908d7f203bab06945466750ce5c09cc2d6261ab1e66eca257c2163d35b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01077505 ([`ctg-observation-nct01077505-2017-06-14-b2ff6b41fc95`](#source-ctg-observation-nct01077505-2017-06-14-b2ff6b41fc95))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01077505 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct01077505-2017-06-14-b2ff6b41fc95`](#source-ctg-observation-nct01077505-2017-06-14-b2ff6b41fc95))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01077505 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct01077505-2017-06-14-b2ff6b41fc95`](#source-ctg-observation-nct01077505-2017-06-14-b2ff6b41fc95))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01077505-2017-06-14-b2ff6b41fc95`](#source-ctg-observation-nct01077505-2017-06-14-b2ff6b41fc95))

### Sources

<a id="source-ctg-observation-nct01077505-2017-06-14-b2ff6b41fc95"></a>
- **ClinicalTrials.gov record NCT01077505 · retained source version 2017-06-14:b2ff6b41fc95bdf2d23ad03eb19de9b283449044da75ef055d92b8667f1dc4c3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01077505) (`ctg-observation-nct01077505-2017-06-14-b2ff6b41fc95`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01077505." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct01077505-albiglutide-v1 SHA-256: 5ec932908d7f203bab06945466750ce5c09cc2d6261ab1e66eca257c2163d35b.

---

<a id="clinicaltrials-gov-nct01098461-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT01098461

> PeptideScanner retained ClinicalTrials.gov record NCT01098461 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-13, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct01098461-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01098461-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct01098461-albiglutide-v1
- Content SHA-256: `4be39edd7a93c9fad2024b3c38d05c8f65a182e545913f99b0390e92362ccb22`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01098461 ([`ctg-observation-nct01098461-2017-01-13-417cd4342a00`](#source-ctg-observation-nct01098461-2017-01-13-417cd4342a00))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01098461 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-13, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct01098461-2017-01-13-417cd4342a00`](#source-ctg-observation-nct01098461-2017-01-13-417cd4342a00))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01098461 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-13, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct01098461-2017-01-13-417cd4342a00`](#source-ctg-observation-nct01098461-2017-01-13-417cd4342a00))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01098461-2017-01-13-417cd4342a00`](#source-ctg-observation-nct01098461-2017-01-13-417cd4342a00))

### Sources

<a id="source-ctg-observation-nct01098461-2017-01-13-417cd4342a00"></a>
- **ClinicalTrials.gov record NCT01098461 · retained source version 2017-01-13:417cd4342a0064ea41bfc7bf0c0744b345387811d33ba5a8b30bc75737a800bb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01098461) (`ctg-observation-nct01098461-2017-01-13-417cd4342a00`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01098461." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct01098461-albiglutide-v1 SHA-256: 4be39edd7a93c9fad2024b3c38d05c8f65a182e545913f99b0390e92362ccb22.

---

<a id="clinicaltrials-gov-nct01098539-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT01098539

> PeptideScanner retained ClinicalTrials.gov record NCT01098539 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct01098539-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-02-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01098539-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct01098539-albiglutide-v1
- Content SHA-256: `2c3e656d3ca464fde43295099ac171be039679053f7e82867f72286c03baae42`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01098539 ([`ctg-observation-nct01098539-2017-02-28-5347f7d5f3ce`](#source-ctg-observation-nct01098539-2017-02-28-5347f7d5f3ce))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01098539 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct01098539-2017-02-28-5347f7d5f3ce`](#source-ctg-observation-nct01098539-2017-02-28-5347f7d5f3ce))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01098539 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct01098539-2017-02-28-5347f7d5f3ce`](#source-ctg-observation-nct01098539-2017-02-28-5347f7d5f3ce))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01098539-2017-02-28-5347f7d5f3ce`](#source-ctg-observation-nct01098539-2017-02-28-5347f7d5f3ce))

### Sources

<a id="source-ctg-observation-nct01098539-2017-02-28-5347f7d5f3ce"></a>
- **ClinicalTrials.gov record NCT01098539 · retained source version 2017-02-28:5347f7d5f3cec593b39d196f3e09df0fc6c63d44980e610543f904ac6cdb7d32** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01098539) (`ctg-observation-nct01098539-2017-02-28-5347f7d5f3ce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01098539." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct01098539-albiglutide-v1 SHA-256: 2c3e656d3ca464fde43295099ac171be039679053f7e82867f72286c03baae42.

---

<a id="clinicaltrials-gov-nct01406262-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT01406262

> PeptideScanner retained ClinicalTrials.gov record NCT01406262 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-08, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct01406262-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-06-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01406262-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct01406262-albiglutide-v1
- Content SHA-256: `de3ea3925a18d668e8b4866c6fc4f5f76b6cd2279af801e4984c0ea9c13c0394`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01406262 ([`ctg-observation-nct01406262-2017-06-08-5f9f39401026`](#source-ctg-observation-nct01406262-2017-06-08-5f9f39401026))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01406262 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-08, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct01406262-2017-06-08-5f9f39401026`](#source-ctg-observation-nct01406262-2017-06-08-5f9f39401026))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01406262 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-08, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct01406262-2017-06-08-5f9f39401026`](#source-ctg-observation-nct01406262-2017-06-08-5f9f39401026))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01406262-2017-06-08-5f9f39401026`](#source-ctg-observation-nct01406262-2017-06-08-5f9f39401026))

### Sources

<a id="source-ctg-observation-nct01406262-2017-06-08-5f9f39401026"></a>
- **ClinicalTrials.gov record NCT01406262 · retained source version 2017-06-08:5f9f394010266e54225e5b7b255bfe81e3461ea2bc28917a7a4d569d19faf04b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01406262) (`ctg-observation-nct01406262-2017-06-08-5f9f39401026`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01406262." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct01406262-albiglutide-v1 SHA-256: de3ea3925a18d668e8b4866c6fc4f5f76b6cd2279af801e4984c0ea9c13c0394.

---

<a id="clinicaltrials-gov-nct01475734-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT01475734

> PeptideScanner retained ClinicalTrials.gov record NCT01475734 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-11, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct01475734-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01475734-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct01475734-albiglutide-v1
- Content SHA-256: `9ef34f322b6c1b33097a9c722cd09fe40f7b1d5478026dd7e41dc96bbd65f017`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01475734 ([`ctg-observation-nct01475734-2017-01-11-d83ed36cc691`](#source-ctg-observation-nct01475734-2017-01-11-d83ed36cc691))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01475734 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-11, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct01475734-2017-01-11-d83ed36cc691`](#source-ctg-observation-nct01475734-2017-01-11-d83ed36cc691))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01475734 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-11, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct01475734-2017-01-11-d83ed36cc691`](#source-ctg-observation-nct01475734-2017-01-11-d83ed36cc691))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01475734-2017-01-11-d83ed36cc691`](#source-ctg-observation-nct01475734-2017-01-11-d83ed36cc691))

### Sources

<a id="source-ctg-observation-nct01475734-2017-01-11-d83ed36cc691"></a>
- **ClinicalTrials.gov record NCT01475734 · retained source version 2017-01-11:d83ed36cc69114e0fffdd896cfd90567320afe73df04160f72bebeb081b39ef3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01475734) (`ctg-observation-nct01475734-2017-01-11-d83ed36cc691`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01475734." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct01475734-albiglutide-v1 SHA-256: 9ef34f322b6c1b33097a9c722cd09fe40f7b1d5478026dd7e41dc96bbd65f017.

---

<a id="clinicaltrials-gov-nct01777282-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT01777282

> PeptideScanner retained ClinicalTrials.gov record NCT01777282 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-05-03, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct01777282-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01777282-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct01777282-albiglutide-v1
- Content SHA-256: `62b1ebedd252b724979b0e07dab5221169bd4f7c958111d3633e1ef1f7db917e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01777282 ([`ctg-observation-nct01777282-2017-05-03-db48876ca689`](#source-ctg-observation-nct01777282-2017-05-03-db48876ca689))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01777282 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-05-03, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct01777282-2017-05-03-db48876ca689`](#source-ctg-observation-nct01777282-2017-05-03-db48876ca689))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01777282 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-05-03, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct01777282-2017-05-03-db48876ca689`](#source-ctg-observation-nct01777282-2017-05-03-db48876ca689))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01777282-2017-05-03-db48876ca689`](#source-ctg-observation-nct01777282-2017-05-03-db48876ca689))

### Sources

<a id="source-ctg-observation-nct01777282-2017-05-03-db48876ca689"></a>
- **ClinicalTrials.gov record NCT01777282 · retained source version 2017-05-03:db48876ca6894c4e6dae0158d2c5ebc23470e9671ac4f53e4e2aeb6d1408ed5d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01777282) (`ctg-observation-nct01777282-2017-05-03-db48876ca689`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01777282." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct01777282-albiglutide-v1 SHA-256: 62b1ebedd252b724979b0e07dab5221169bd4f7c958111d3633e1ef1f7db917e.

---

<a id="clinicaltrials-gov-nct02229227-albiglutide-v1"></a>

## ClinicalTrials.gov record NCT02229227

> PeptideScanner retained ClinicalTrials.gov record NCT02229227 at 2026-11-16T17:45:42.793Z. Its registry update date was 2020-11-27, and PeptideScanner's reviewed identity mapping was albiglutide.

- Evidence object: `story:clinicaltrials-gov-nct02229227-albiglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-11-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02229227-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct02229227-albiglutide-v1
- Content SHA-256: `39fb526095645230d234caf5a79617234ae9668982c77c6d81329d18c71f60e0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02229227 ([`ctg-observation-nct02229227-2020-11-27-a7d2d95ebe74`](#source-ctg-observation-nct02229227-2020-11-27-a7d2d95ebe74))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02229227 at 2026-11-16T17:45:42.793Z. Its registry update date was 2020-11-27, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct02229227-2020-11-27-a7d2d95ebe74`](#source-ctg-observation-nct02229227-2020-11-27-a7d2d95ebe74))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02229227 at 2026-11-16T17:45:42.793Z. Its registry update date was 2020-11-27, and PeptideScanner's reviewed identity mapping was albiglutide. ([`ctg-observation-nct02229227-2020-11-27-a7d2d95ebe74`](#source-ctg-observation-nct02229227-2020-11-27-a7d2d95ebe74))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02229227-2020-11-27-a7d2d95ebe74`](#source-ctg-observation-nct02229227-2020-11-27-a7d2d95ebe74))

### Sources

<a id="source-ctg-observation-nct02229227-2020-11-27-a7d2d95ebe74"></a>
- **ClinicalTrials.gov record NCT02229227 · retained source version 2020-11-27:a7d2d95ebe7464ca1111fccfade23babd44eeb3638aedb95e340a62302e5a64d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02229227) (`ctg-observation-nct02229227-2020-11-27-a7d2d95ebe74`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02229227." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#clinicaltrials-gov-nct02229227-albiglutide-v1 SHA-256: 39fb526095645230d234caf5a79617234ae9668982c77c6d81329d18c71f60e0.

---

<a id="fda-drugs-bla125431-v1"></a>

## Drugs@FDA application BLA125431

> The official Drugs@FDA dataset lists original submission 1 for BLA 125431 with status AP dated 2014-04-15, and names albiglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-bla125431:v1`
- Evidence domain: Regulatory
- Date in source: 2014-04-15
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-bla125431/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#fda-drugs-bla125431-v1
- Content SHA-256: `66efb8c0be238d3fe6e6bedb933280b668359f86bd9fb15e70aec797acf2e402`

### Claims and source pins

#### Headline

Drugs@FDA application BLA125431 ([`fda-drugs-bla125431-2014-04-15-d61c7f1662d4`](#source-fda-drugs-bla125431-2014-04-15-d61c7f1662d4))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for BLA 125431 with status AP dated 2014-04-15, and names albiglutide among the application record's active ingredients. ([`fda-drugs-bla125431-2014-04-15-d61c7f1662d4`](#source-fda-drugs-bla125431-2014-04-15-d61c7f1662d4))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for BLA 125431 with status AP dated 2014-04-15, and names albiglutide among the application record's active ingredients. ([`fda-drugs-bla125431-2014-04-15-d61c7f1662d4`](#source-fda-drugs-bla125431-2014-04-15-d61c7f1662d4))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-bla125431-2014-04-15-d61c7f1662d4`](#source-fda-drugs-bla125431-2014-04-15-d61c7f1662d4))

### Sources

<a id="source-fda-drugs-bla125431-2014-04-15-d61c7f1662d4"></a>
- **Drugs@FDA application BLA125431 · original submission status AP · 2014-04-15 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22BLA125431%22&limit=1) (`fda-drugs-bla125431-2014-04-15-d61c7f1662d4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application BLA125431." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#fda-drugs-bla125431-v1 SHA-256: 66efb8c0be238d3fe6e6bedb933280b668359f86bd9fb15e70aec797acf2e402.

---

<a id="federal-register-2016-13797-v1"></a>

## Federal Register notice 2016-13797

> The Federal Register published notice 2016-13797, attributed to FDA and its parent HHS department, on 2016-06-10. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,” and PeptideScanner's exact reviewed identity mapping connects the document to Albiglutide.

- Evidence object: `story:federal-register-2016-13797:v1`
- Evidence domain: Regulatory
- Date in source: 2016-06-10
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2016-13797/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#federal-register-2016-13797-v1
- Content SHA-256: `f7fce2c1d16562725a8926483abdf644610acabea2f4cb4b9dfca6521ad69a3b`

### Claims and source pins

#### Headline

Federal Register notice 2016-13797 ([`federal-register-2016-13797-274dd8c5c933`](#source-federal-register-2016-13797-274dd8c5c933))

#### Summary

The Federal Register published notice 2016-13797, attributed to FDA and its parent HHS department, on 2016-06-10. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,” and PeptideScanner's exact reviewed identity mapping connects the document to Albiglutide. ([`federal-register-2016-13797-274dd8c5c933`](#source-federal-register-2016-13797-274dd8c5c933))

#### Paragraph 1

The Federal Register published notice 2016-13797, attributed to FDA and its parent HHS department, on 2016-06-10. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,” and PeptideScanner's exact reviewed identity mapping connects the document to Albiglutide. ([`federal-register-2016-13797-274dd8c5c933`](#source-federal-register-2016-13797-274dd8c5c933))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2016-13797-274dd8c5c933`](#source-federal-register-2016-13797-274dd8c5c933))

### Sources

<a id="source-federal-register-2016-13797-274dd8c5c933"></a>
- **Federal Register notice 2016-13797 · published 2016-06-10 · Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2016-06-10/pdf/2016-13797.pdf) (`federal-register-2016-13797-274dd8c5c933`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2016-13797." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#federal-register-2016-13797-v1 SHA-256: f7fce2c1d16562725a8926483abdf644610acabea2f4cb4b9dfca6521ad69a3b.

---

<a id="pubmed-pmid-25216888-albiglutide-v1"></a>

## Apremilast, albiglutide, and empagliflozin.

> PubMed lists PMID 25216888 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2014 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25216888-albiglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-06-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25216888-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#pubmed-pmid-25216888-albiglutide-v1
- Content SHA-256: `1a7a85898472b98f17904294220826f4bb733fb013ca5246072e8aae233dc9e7`

### Claims and source pins

#### Headline

Apremilast, albiglutide, and empagliflozin. ([`pubmed-observation-pmid-25216888-2015-06-15-e0441a206b03`](#source-pubmed-observation-pmid-25216888-2015-06-15-e0441a206b03))

#### Summary

PubMed lists PMID 25216888 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2014 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25216888-2015-06-15-e0441a206b03`](#source-pubmed-observation-pmid-25216888-2015-06-15-e0441a206b03))

#### Paragraph 1

PubMed lists PMID 25216888 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2014 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25216888-2015-06-15-e0441a206b03`](#source-pubmed-observation-pmid-25216888-2015-06-15-e0441a206b03))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25216888-2015-06-15-e0441a206b03`](#source-pubmed-observation-pmid-25216888-2015-06-15-e0441a206b03))

### Sources

<a id="source-pubmed-observation-pmid-25216888-2015-06-15-e0441a206b03"></a>
- **Apremilast, albiglutide, and empagliflozin. · retained source version 1:2015-06-15:current:e0441a206b03fbeebb0f5909d150a3d64f0d398dcae63635621817b35b34d7a4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25216888/) (`pubmed-observation-pmid-25216888-2015-06-15-e0441a206b03`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Apremilast, albiglutide, and empagliflozin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#pubmed-pmid-25216888-albiglutide-v1 SHA-256: 1a7a85898472b98f17904294220826f4bb733fb013ca5246072e8aae233dc9e7.

---

<a id="pubmed-pmid-28085780-albiglutide-v1"></a>

## Albiglutide for the treatment of type 2 diabetes mellitus.

> PubMed lists PMID 28085780 in The Nurse practitioner as Journal Article, with publication-date metadata of 2017-02-12 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28085780-albiglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28085780-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#pubmed-pmid-28085780-albiglutide-v1
- Content SHA-256: `b782aa97f2304f9243adbe2d2f89c359b8a4b30f41b3ddc6f20a9f6a2b91f021`

### Claims and source pins

#### Headline

Albiglutide for the treatment of type 2 diabetes mellitus. ([`pubmed-observation-pmid-28085780-2019-07-18-ca7d24f9bad8`](#source-pubmed-observation-pmid-28085780-2019-07-18-ca7d24f9bad8))

#### Summary

PubMed lists PMID 28085780 in The Nurse practitioner as Journal Article, with publication-date metadata of 2017-02-12 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28085780-2019-07-18-ca7d24f9bad8`](#source-pubmed-observation-pmid-28085780-2019-07-18-ca7d24f9bad8))

#### Paragraph 1

PubMed lists PMID 28085780 in The Nurse practitioner as Journal Article, with publication-date metadata of 2017-02-12 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28085780-2019-07-18-ca7d24f9bad8`](#source-pubmed-observation-pmid-28085780-2019-07-18-ca7d24f9bad8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28085780-2019-07-18-ca7d24f9bad8`](#source-pubmed-observation-pmid-28085780-2019-07-18-ca7d24f9bad8))

### Sources

<a id="source-pubmed-observation-pmid-28085780-2019-07-18-ca7d24f9bad8"></a>
- **Albiglutide for the treatment of type 2 diabetes mellitus. · retained source version 1:2019-07-18:current:ca7d24f9bad8bbc367e96cbe7a86a071c19cd79aa46b8581d99c06afa7963a84** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28085780/) (`pubmed-observation-pmid-28085780-2019-07-18-ca7d24f9bad8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Albiglutide for the treatment of type 2 diabetes mellitus." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#pubmed-pmid-28085780-albiglutide-v1 SHA-256: b782aa97f2304f9243adbe2d2f89c359b8a4b30f41b3ddc6f20a9f6a2b91f021.

---

<a id="pubmed-pmid-28409609-albiglutide-v1"></a>

## Albiglutide (Tanzeum) for Diabetes Mellitus.

> PubMed lists PMID 28409609 in American family physician as Journal Article, Review, with publication-date metadata of 2017-04-15 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28409609-albiglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28409609-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#pubmed-pmid-28409609-albiglutide-v1
- Content SHA-256: `6b122800526e52153943c3f853e87426df2b49a6635567aa5740b7b747d1d5a5`

### Claims and source pins

#### Headline

Albiglutide (Tanzeum) for Diabetes Mellitus. ([`pubmed-observation-pmid-28409609-2018-11-15-b70b136a9626`](#source-pubmed-observation-pmid-28409609-2018-11-15-b70b136a9626))

#### Summary

PubMed lists PMID 28409609 in American family physician as Journal Article, Review, with publication-date metadata of 2017-04-15 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28409609-2018-11-15-b70b136a9626`](#source-pubmed-observation-pmid-28409609-2018-11-15-b70b136a9626))

#### Paragraph 1

PubMed lists PMID 28409609 in American family physician as Journal Article, Review, with publication-date metadata of 2017-04-15 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28409609-2018-11-15-b70b136a9626`](#source-pubmed-observation-pmid-28409609-2018-11-15-b70b136a9626))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28409609-2018-11-15-b70b136a9626`](#source-pubmed-observation-pmid-28409609-2018-11-15-b70b136a9626))

### Sources

<a id="source-pubmed-observation-pmid-28409609-2018-11-15-b70b136a9626"></a>
- **Albiglutide (Tanzeum) for Diabetes Mellitus. · retained source version 1:2018-11-15:current:b70b136a9626db697b26f0f695d4ab1e21b22ffb4d2fa91a83152b606bbb958a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28409609/) (`pubmed-observation-pmid-28409609-2018-11-15-b70b136a9626`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Albiglutide (Tanzeum) for Diabetes Mellitus." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#pubmed-pmid-28409609-albiglutide-v1 SHA-256: 6b122800526e52153943c3f853e87426df2b49a6635567aa5740b7b747d1d5a5.

---

<a id="pubmed-pmid-32219329-albiglutide-v1"></a>

## Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.

> PubMed lists PMID 32219329 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2020-06-01 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32219329-albiglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-02-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32219329-albiglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#pubmed-pmid-32219329-albiglutide-v1
- Content SHA-256: `6da96bee96c23b515448139082ea51b891e48c1f7047f13db55a9c1752f88799`

### Claims and source pins

#### Headline

Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. ([`pubmed-observation-pmid-32219329-2021-02-01-2a247f630cab`](#source-pubmed-observation-pmid-32219329-2021-02-01-2a247f630cab))

#### Summary

PubMed lists PMID 32219329 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2020-06-01 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32219329-2021-02-01-2a247f630cab`](#source-pubmed-observation-pmid-32219329-2021-02-01-2a247f630cab))

#### Paragraph 1

PubMed lists PMID 32219329 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2020-06-01 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32219329-2021-02-01-2a247f630cab`](#source-pubmed-observation-pmid-32219329-2021-02-01-2a247f630cab))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32219329-2021-02-01-2a247f630cab`](#source-pubmed-observation-pmid-32219329-2021-02-01-2a247f630cab))

### Sources

<a id="source-pubmed-observation-pmid-32219329-2021-02-01-2a247f630cab"></a>
- **Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. · retained source version 1:2021-02-01:current:2a247f630cab5331a124bd7206e227951d5f98188e1c950d0766cfccffe7bfbc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32219329/) (`pubmed-observation-pmid-32219329-2021-02-01-2a247f630cab`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/albiglutide.json#pubmed-pmid-32219329-albiglutide-v1 SHA-256: 6da96bee96c23b515448139082ea51b891e48c1f7047f13db55a9c1752f88799.

